Unknown

Dataset Information

0

Quality of life, long-term survivors and long-term outcome from the ABC-02 study.


ABSTRACT: The ABC-02 (Advanced Biliary Tract Cancer) study established cisplatin and gemcitabine (CisGem) as the standard first-line chemotherapy for patients with locally advanced or metastatic biliary tract cancer (BTC). We examine quality of life (QoL), describe the long-term survivors and provide a long-term outcome.A total of 410 BTC patients were randomised to receive either CisGem or gemcitabine alone (Gem); 324 patients consented to complete EORTC QLQ-C30 and EORTC QLQ-PAN26 QoL questionnaires; 268 (83%) patients returned at least one QoL questionnaire (134 in each arm). Long-term survivors were defined as those surviving over 2 years and we performed a final analysis of the primary outcome; overall survival (OS).Most QoL scales showed a trend favouring the combined CisGem arm, including functional and symptomatic scales, although the differences were not statistically significant. Forty-five (11%)) patients survived at least 2 years (34 received CisGem and 11 Gem) and 21 (5%) 3 years or more (14 received CisGem and 7 Gem). After a median follow-up of 9.2 months and 398 deaths, the median OS was 11.7 months for CisGem and 8.1 months for Gem (hazard ratio (HR)=0.65, 95% CI: 0.53-0.79, P<0.001).The survival advantage of CisGem compared to Gem was not associated with an improvement or deterioration of QoL. Long-term survivors were more likely to have received CisGem and the long-term OS is identical to that previously described.

SUBMITTER: Bridgewater J 

PROVIDER: S-EPMC4984909 | biostudies-literature | 2016 Apr

REPOSITORIES: biostudies-literature

altmetric image

Publications

Quality of life, long-term survivors and long-term outcome from the ABC-02 study.

Bridgewater John J   Lopes Andre A   Palmer Daniel D   Cunningham David D   Anthoney Alan A   Maraveyas Anthony A   Madhusudan Srinivasan S   Iveson Tim T   Valle Juan J   Wasan Harpreet H  

British journal of cancer 20160401 9


<h4>Background</h4>The ABC-02 (Advanced Biliary Tract Cancer) study established cisplatin and gemcitabine (CisGem) as the standard first-line chemotherapy for patients with locally advanced or metastatic biliary tract cancer (BTC). We examine quality of life (QoL), describe the long-term survivors and provide a long-term outcome.<h4>Methods</h4>A total of 410 BTC patients were randomised to receive either CisGem or gemcitabine alone (Gem); 324 patients consented to complete EORTC QLQ-C30 and EOR  ...[more]

Similar Datasets

| S-EPMC10698799 | biostudies-literature
| S-EPMC3241852 | biostudies-literature
| S-EPMC8253876 | biostudies-literature
| S-EPMC4304781 | biostudies-other
| S-EPMC9998537 | biostudies-literature
| S-EPMC8039509 | biostudies-literature
| S-EPMC3251903 | biostudies-literature
| S-EPMC4974120 | biostudies-other
| S-EPMC4949079 | biostudies-literature
| S-EPMC3360640 | biostudies-literature